InvestorsHub Logo

couldbebetter

03/30/19 1:37 PM

#184659 RE: Crikker #184657

Crikker, My point in using ABBV was not to compare it to AMRN
today...but to what AMRN may eventually become in a GIA scenario
perhaps 5 or 6 years from now. ABBV has substantial debt...AMRN
has none. (Not counting the royalty thingy.)

A GIA will require diversification by AMRN...perhaps
acquiring companies such as VKTX and AVXL. Such acquisitions
will require dilution or debt for those companies as well as
money for further testing of new medications.

In a GIA scenario, the sales force would likely be expanded
further and that may reduce profit margins. You are correct
that ABBV today is a value stock. In 5 or 6 years from now
AMRN may be seen as a value stock.

In any case John Thero has had many years to formulate his
game plan for AMRN. It will be interesting to watch it unfold
and hopefully rewarding for the long-term investors here.